Source: FierceBiotech

Oxford BioTherapeutics: Oxford BioTherapeutics raids Celgene for CMO as I-O trial plan takes shape

Oxford BioTherapeutics has lured Abderrahim Fandi, M.D., Ph.D., away from Celgene to serve as its CMO. The appointment puts Fandi in charge of developing OBT's immuno-oncology candidates.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Christian Rohlff's photo - Founder & CEO of OBT

Founder & CEO

Christian Rohlff

CEO Approval Rating

86/100

OBT is a biotechnology company that focuses on the discovery and development of therapeutics for the treatment of cancer. Read more